GDF15: from biomarker to target in cancer cachexia

Area of Science:

• Oncology
• Metabolic Disorders
• Immunology

Background:

• Cancer cachexia is a prevalent, debilitating condition in advanced cancer patients, marked by significant weight loss.
• Current treatments for cancer cachexia are largely ineffective, highlighting an unmet clinical need.
• Growth differentiation factor 15 (GDF15) is a known biomarker associated with various diseases, including cancer.

Purpose of the Study:

• To review the current literature on the role of GDF15 in cancer cachexia.
• To elucidate the mechanisms by which GDF15 influences metabolism and immunosuppression in cancer.
• To highlight the therapeutic potential of targeting GDF15 in cancer patients.

Main Methods:

• Literature synthesis of existing research on GDF15 and cancer cachexia.
• Analysis of GDF15's mechanism of action via GFRAL receptors in the hindbrain.
• Review of recent clinical trial data on GDF15-targeted therapies.

Main Results:

• GDF15 plays a critical role in regulating food intake, body weight, and insulin sensitivity.
• GDF15 influences the tumor microenvironment and systemic immunosuppression.
• Clinical trials indicate GDF15 targeting can enhance immunotherapy efficacy, physical activity, appetite, and weight gain.

Conclusions:

• GDF15 is a key mediator in cancer cachexia, affecting both metabolic and immune processes.
• Targeting the GDF15 pathway presents a promising therapeutic strategy for managing cancer cachexia and improving patient quality of life.
• Further research and clinical development of GDF15 inhibitors are warranted.